These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24256017)

  • 1. [Regulatory procedures of non-interventional post-authorization studies in Spain].
    Vicente Sánchez MP; González Bermejo D; Macías Saint-Gerons D; de la Fuente Honrubia C
    Farm Hosp; 2013; 37(6):530-3. PubMed ID: 24256017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridge the gap: The need for harmonized regulatory and ethical standards for postmarketing observational studies.
    Urushihara H; Parmenter L; Tashiro S; Matsui K; Dreyer N
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1299-1306. PubMed ID: 28815982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-interventional post-authorisation studies in Spain: justification and basis of a new regulation].
    De La Fuente Honrubia C; De Abajo Iglesias FJ; García Del Pozo J; Vargas Castrillón E
    Med Clin (Barc); 2010 May; 134(13):605-11. PubMed ID: 20304440
    [No Abstract]   [Full Text] [Related]  

  • 5. [Post-authorisation studies in Spain: legal frame, problems and solutions].
    Bernard C; Molina Figueras X
    Med Clin (Barc); 2009 Nov; 133(17):676-81. PubMed ID: 19850305
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the revised electromagnetic compatibility standard.
    Bozec D; Hayes DJ
    Med Device Technol; 2004 Oct; 15(8):33-4, 36. PubMed ID: 16225272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International guidelines on post-authorisation research and surveillance. European Economic Community.
    Herbold M
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):62-4. PubMed ID: 9035230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving process of European combination product review, Part II.
    Donawa ME
    Med Device Technol; 2008; 19(7):26, 28-31. PubMed ID: 19133625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies.
    O'Neill RT
    Stat Med; 1998 Aug 15-30; 17(15-16):1851-8; discussion 1859-62. PubMed ID: 9749452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sense and nonsense of post-authorization surveillance].
    de Mey C
    Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347
    [No Abstract]   [Full Text] [Related]  

  • 13. Meeting US and European supplier control requirements.
    Donawa M
    Med Device Technol; 2009; 20(3):24-7. PubMed ID: 19626952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International data standards for hospital-based drug surveillance.
    Kurata JH; Overhage M; Gabrieli E; Jones JK
    MD Comput; 1995; 12(1):50-7. PubMed ID: 7854080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European requirements for product returns.
    Donawa M
    Med Device Technol; 2005 Nov; 16(9):28-31. PubMed ID: 16438446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Channeling postmarketing patient data into pharmaceutical regulatory systems.
    Barbosa MD; Smith DD
    Drug Discov Today; 2014 Dec; 19(12):1897-912. PubMed ID: 25086288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spain's competent authority initiatives.
    Luna CA
    Stud Health Technol Inform; 1996; 28():112-5. PubMed ID: 10164086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 19. European medical device regulation: a new era?
    Donawa M
    Med Device Technol; 2004 Dec; 15(10):30-1. PubMed ID: 16225282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing new European vigilance procedures.
    Donawa M
    Med Device Technol; 2007; 18(7):34, 36-7. PubMed ID: 18075133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.